...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios.
【24h】

Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios.

机译：托吡酯，拉莫三嗪和苯巴比妥的临床药理学：使用比值比比较疗效和副作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Clinical pharmacologists, neurologists, internists, and all health care givers must consider the efficacy, safety, and side effect profile of a given antiepileptic drug (AED) when determining which drug is best for a given patient. The first purpose of this paper is to address whether the new teach those interested in clinical pharmacology about the use of Web-based information access to answer a neurology/clinical pharmacology problem: to compare the efficacy and side effects of topiramate versus lamotrigine versus phenobarbital using odds ratios. Cost of all three AEDs was also compared. A number of new AEDs, including topiramate and lamotrigine, have been developed for chronic focal and secondarily generalized epileptic seizures. Efficacy of these drugs as anticonvulsants does not seem to be superior to that of traditional anticonvulsants such as phenobarbital. However, the advantage of the new drugs is a different spectrum of possible adverse events. Newer AEDs may or may not induce sedation and may minimize noncompliance by reducing side effects of lethargy and cognitive impairment. The difficulty in achieving therapeutic dosage because of side effects makes one consider whether these agents are "better" than the oldest and most side effect-prone AED, phenobarbital. The new AEDs have less frequent interactions, leading to improved tolerability with comedication. This exercise compares two "new" AEDs, topiramate and lamotrigine, with phenobarbital by evaluating efficacies and side effects using relative odds ratios, a method commonly used in drug development research. Development of new algorithms and/or new knowledge will bring beneficial tools to all clinical pharmacologists.
机译：在确定哪种药物最适合特定患者时，临床药理学家，神经病学家，内科医生和所有医疗服务提供者必须考虑特定抗癫痫药物（AED）的功效，安全性和副作用。本文的第一个目的是解决该新产品是否教给对临床药理学感兴趣的人使用基于Web的信息访问来回答神经学/临床药理学问题：比较托吡酯，拉莫三嗪和苯巴比妥的疗效和副作用比值比（统计学用。还比较了所有三种AED的成本。已经开发出许多新的抗癫痫药，包括托吡酯和拉莫三嗪，用于慢性局灶性和继发性全身性癫痫发作。这些药物作为抗惊厥药的功效似乎并不优于苯巴比妥等传统抗惊厥药。但是，新药的优势在于可能发生不良事件的可能性不同。较新的AED可能会或可能不会引起镇静作用，并可能通过减少嗜睡和认知障碍的副作用来最大程度地减少违规行为。由于副作用而难以达到治疗剂量的问题使得人们不得不考虑这些药物是否比最古老，最容易发生副作用的AED苯巴比妥“更好”。新的AED具有较少的交互作用，从而提高了喜剧性的耐受性。本练习通过使用相对比值比（一种在药物开发研究中常用的方法）评估疗效和副作用，将两种“新” AED（托吡酯和拉莫三嗪）与苯巴比妥进行了比较。新算法和/或新知识的开发将为所有临床药理学家带来有益的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号